Pura Vida Investments LLC bought a new stake in Kala Pharmaceuticals Inc (NASDAQ:KALA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 215,870 shares of the company’s stock, valued at approximately $1,056,000. Pura Vida Investments LLC owned approximately 0.64% of Kala Pharmaceuticals at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of KALA. BlackRock Inc. lifted its holdings in shares of Kala Pharmaceuticals by 29.2% during the fourth quarter. BlackRock Inc. now owns 1,427,672 shares of the company’s stock worth $6,980,000 after purchasing an additional 322,311 shares during the period. Athyrium Capital Management LP acquired a new position in shares of Kala Pharmaceuticals during the fourth quarter worth $6,520,000. Vanguard Group Inc lifted its holdings in shares of Kala Pharmaceuticals by 8.0% during the third quarter. Vanguard Group Inc now owns 510,295 shares of the company’s stock worth $5,036,000 after purchasing an additional 37,738 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Kala Pharmaceuticals by 8.0% during the third quarter. Vanguard Group Inc. now owns 510,295 shares of the company’s stock worth $5,036,000 after purchasing an additional 37,738 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Kala Pharmaceuticals by 62.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 255,760 shares of the company’s stock worth $1,251,000 after purchasing an additional 98,591 shares during the period. Hedge funds and other institutional investors own 67.96% of the company’s stock.
A number of equities analysts have recently commented on KALA shares. Jefferies Financial Group started coverage on shares of Kala Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $15.00 price target on the stock. BidaskClub upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. Wedbush set a $51.00 price target on shares of Kala Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, January 16th. Zacks Investment Research upgraded shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a report on Wednesday, January 2nd. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Kala Pharmaceuticals in a report on Thursday, December 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $20.58.
KALA stock opened at $8.67 on Friday. The firm has a market capitalization of $285.06 million, a P/E ratio of -3.50 and a beta of 1.73. The company has a current ratio of 6.34, a quick ratio of 6.27 and a debt-to-equity ratio of 0.30. Kala Pharmaceuticals Inc has a 12-month low of $4.03 and a 12-month high of $18.30.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://transcriptdaily.com/2019/03/17/215870-shares-in-kala-pharmaceuticals-inc-kala-purchased-by-pura-vida-investments-llc.html.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Read More: What are the most popular ETFs
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.